StreetAlpha.app
Home › Stocks › BIIB

Biogen Inc. (BIIB)

Healthcare
$250.79
▼ −0.34%
LAST CLOSE · NOV 17

Biogen is a Cambridge, Massachusetts biopharmaceutical company that develops and sells medicines for neurology and rare diseases. It last closed at $250.79 on Nov 17, down 0.34% on the day. BIIB reports earnings on Fri, Feb 5, 2027. The average 12-month price target from 17 analysts is $273.29 (+9.0% from the last close), with a high of $310.00 and a low of $225.00. Analyst consensus is Strong Buy, based on the latest ratings from 17 firms (13 buy, 4 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in BIIB, 25% of them bullish and 75% bearish. In the past 30 days there were 4 dark pool prints totaling $3.3M, the largest $1.1M.

AI Auto Pilots
Is BIIB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$10.3B
+2.3% vs a year ago
Net income
$347.5M
−78.4% vs a year ago
EPS (diluted)
$2.31
−78.9% vs a year ago
Free cash flow
$2.1B
20.1% margin
Valuation
Market cap
$37.1B
147.8M shares
P/E
108.6
Price over 12 month EPS
Price to sales
3.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.3B
At Sep 30
Debt
$7.3B
At Sep 30
Shares outstanding
147.8M
At Oct 26
CEOMichel Vounatsos
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $11.0B$11.0BFY2021FY2022: $10.2B$10.2BFY2022FY2023: $9.8B$9.8BFY2023FY2024: $9.7B$9.7BFY2024FY2025: $9.9B$9.9BFY2025

From BIIB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 28). Last 12 months adds up the four latest quarters.

Next report
Feb 5
2027 · Time not announced
Consensus EPS forecast
$2.79
$2.61B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 17 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
17firms
13 Buy4 Hold0 Sell
Each firm's latest rating on BIIB in the past 90 days
Average 12-month target
$273.29
▲ 9.0% upside

Based on 17 analysts who set a price target on BIIB in the past 90 days. The average target is $273.29, with a high of $310.00 and a low of $225.00, compared with the last close of $250.79.

Low $225.00Avg $273.29High $310.00
Blue marker: last close $250.79
Highest target$310.00
Average target$273.29
Lowest target$225.00
Latest rating changes
Piper SandlerTarget raised
Nov 9Buy$245 → $305
GuggenheimMaintained
Nov 2Buy$300
HC Wainwright & Co.Maintained
Nov 2Buy$270
Canaccord GenuityTarget raised
Oct 29Buy$248 → $272
Argus ResearchUpgrade
Oct 29Buy$280
DateFirmActionRatingPrice target
Nov 9Piper SandlerTarget raisedBuy$245 → $305
Nov 2GuggenheimMaintainedBuy$300
Nov 2HC Wainwright & Co.MaintainedBuy$270
Oct 29Canaccord GenuityTarget raisedBuy$248 → $272
Oct 29Argus ResearchUpgradeBuy$280
Loading…

Technical Analysis

BIIB · as of the Nov 17 close · updated after every close
Uptrend

The stock is 0% above its 20 day and 6% above its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 56). The nearest support is the Pivot at $250.59, and the nearest resistance the Pivot R1 at $252.92.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.9%/day
Key levels
$261.0052 week high+4.1%
$254.41Swing high (Oct 22)+1.4%
$252.92Pivot R1+0.8%
$250.79Last close
$250.59Pivot−0.1%
$250.5220 day average−0.1%
$248.46Pivot S1−0.9%
$243.03Swing low (Oct 28)−3.1%
$234.7350 day average−6.4%
$222.09100 day average−11.4%
$205.87200 day average−17.9%
$160.3652 week low−36.1%
Indicators
RSI (14)56.04Middle of its rangeNeutral
MACD4.90Below its signal lineBearish
Stochastic56.9Middle of its rangeNeutral
ADX (14)26.7Trending up
Williams %R-48.6Oversold below −80, overbought above −20Neutral
CCI (20)-0.1Oversold below −100, overbought above 100Neutral
Rate of change+0.8%Change over 10 sessionsBullish
ATR (14)$7.29Typical daily range, 2.9% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for BIIB

What happened before

See how BIIB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish1 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow BIIB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BIIB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
4
Bullish
1
25%
Bearish
3
75%
Date span
Oct 22 – Nov 17
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$3.3M
Largest print
$1.1M
Loading…

BIIB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲496 buying vs 407 selling
  • ▼Held by funds -2.0 pts
  • ▲Funds holding +11
  • ●Superinvestors: 2 added, 2 cut
  • ▼Put/call 0.48 to 0.77
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,0561,045+1.1%
In funds' top 10139+44.4%
Held by funds94.8%96.8%−2.0 pts
New / increased91 / 405111 / 425−7.5%
Reduced / sold out337 / 70292 / 84+8.2%
Put/call ratio0.770.48+61.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BIIB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BIIB Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
—
 
Left in program
$2.0B
5.5% of value
Shares outstanding, 12 months
+0.8%
More shares
Last quarter
$0
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
—
 
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 28, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIIB is in one of them and how their past BIIB trades turned out.

BIIB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BIIB in an article yet. Here's the latest on the wider market.

BIIB Congress Trades

All congress trades →
Trades, 12 months
15
Buys
10
67%
Sells
5
33%
People
6
Last filed Oct 8
Who traded BIIB · since 2014
Latest 5 filings of 110
$1K – $15KTraded Sep 24, 2026Filed Oct 8, 2026
$1K – $15KTraded Sep 11, 2026Filed Oct 7, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$1K – $15KTraded Aug 18, 2026Filed Sep 1, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
PersonTypeAmountTradedFiledDelay
Maria Elvira SalazarRSell$1K – $15KSep 24, 2026Oct 8, 202614 d
Ro KhannaD · CASell$1K – $15KSep 11, 2026Oct 7, 202626 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d
Kevin HernR · OKSell$1K – $15KAug 18, 2026Sep 1, 202614 d
Alan ArmstrongHouseBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Biogen

Biogen is a biopharmaceutical company based in Cambridge, Massachusetts. It discovers, develops and sells medicines for serious and complex diseases, with a focus on neurology, specialized immunology and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and ALS, along with biosimilars of widely used biologic drugs. Its customers include patients and healthcare providers, and it also works with partners such as Eisai and Genentech on other medicines.

Headquarters
Cambridge, MA
Founded
1978